Evidence map›Paper›PMID 37043509›Full record

ArticlePloS one2023

Combined action of albumin and heparin regulates lipoprotein lipase oligomerization, stability, and ligand interactions.

Robert Risti, Kathryn H Gunn, Kristofer Hiis-Hommuk, Natjan-Naatan Seeba, Hamed Karimi, Ly Villo, Marko Vendelin, Saskia B Neher, Aivar Lõokene

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Robert RistiDepartment of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia.ORCID 0000-0001-5623-8235
Kathryn H GunnDepartment of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Kristofer Hiis-HommukLaboratory of Systems Biology, Department of Cybernetics, Tallinn University of Technology, Tallinn, Estonia.
Natjan-Naatan SeebaDepartment of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia.ORCID 0000-0003-2044-8710
Hamed KarimiLaboratory of Systems Biology, Department of Cybernetics, Tallinn University of Technology, Tallinn, Estonia.ORCID 0000-0003-0275-5311
Ly VilloDepartment of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia.
Marko VendelinLaboratory of Systems Biology, Department of Cybernetics, Tallinn University of Technology, Tallinn, Estonia.ORCID 0000-0002-6459-0391
Saskia B NeherDepartment of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Aivar LõokeneDepartment of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia.ORCID 0000-0002-0157-727X
Tallinn University of Technology · EEUniversity of North Carolina at Chapel Hill · US

Funding

Investigation of the Molecular Mechanisms of Lipoprotein Lipase InhibitorsR01HL125654 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NEHER, SASKIA · 2015 to 2024
$3.8M
NHLBI NIH HHS R01 HL125654
6 · The paper itself

Abstract

Lipoprotein lipase (LPL), a crucial enzyme in the intravascular hydrolysis of triglyceride-rich lipoproteins, is a potential drug target for the treatment of hypertriglyceridemia. The activity and stability of LPL are influenced by a complex ligand network. Previous studies performed in dilute solutions suggest that LPL can appear in various oligomeric states. However, it was not known how the physiological environment, that is blood plasma, affects the action of LPL. In the current study, we demonstrate that albumin, the major protein component in blood plasma, has a significant impact on LPL stability, oligomerization, and ligand interactions. The effects induced by albumin could not solely be reproduced by the macromolecular crowding effect. Stabilization, isothermal titration calorimetry, and surface plasmon resonance studies revealed that albumin binds to LPL with affinity sufficient to form a complex in both the interstitial space and the capillaries. Negative stain transmission electron microscopy and raster image correlation spectroscopy showed that albumin, like heparin, induced reversible oligomerization of LPL. However, the albumin induced oligomers were structurally different from heparin-induced filament-like LPL oligomers. An intriguing observation was that no oligomers of either type were formed in the simultaneous presence of albumin and heparin. Our data also suggested that the oligomer formation protected LPL from the inactivation by its physiological regulator angiopoietin-like protein 4. The concentration of LPL and its environment could influence whether LPL follows irreversible inactivation and aggregation or reversible LPL oligomer formation, which might affect interactions with various ligands and drugs. In conclusion, the interplay between albumin and heparin could provide a mechanism for ensuring the dissociation of heparan sulfate-bound LPL oligomers into active LPL upon secretion into the interstitial space.

Indexed as

HeparinLipoprotein LipaseAlbuminsAngiopoietin-Like Protein 4HydrolysisLigandsTriglyceridesAlbuminsAngiopoietin-Like Protein 4HeparinLigandsLipoprotein LipaseTriglycerides

Identifiers

PMID37043509
PMCPMC10096250
OpenAlexW4365136146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.